
==== Front
Clin Exp Med
Clin Exp Med
Clinical and Experimental Medicine
1591-8890
1591-9528
Springer International Publishing Cham

39230596
1478
10.1007/s10238-024-01478-x
Review
Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis
Mangoni Arduino A. arduino.mangoni@flinders.edu.au

124
Zinellu Angelo 3
1 https://ror.org/01kpzv902 grid.1014.4 0000 0004 0367 2697 Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
2 https://ror.org/020aczd56 grid.414925.f 0000 0000 9685 0624 Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia
3 https://ror.org/01bnjbv91 grid.11450.31 0000 0001 2097 9138 Department of Biomedical Sciences, University of Sassari, Sassari, Italy
4 https://ror.org/01kpzv902 grid.1014.4 0000 0004 0367 2697 Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Bedford Park, SA 5042 Australia
4 9 2024
4 9 2024
2024
24 1 20728 4 2024
23 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Existing challenges with the early diagnosis of rheumatoid arthritis (RA) and active disease, mainly by non-rheumatologists, have prompted the search for novel biomarkers. Elevations in indices derived from blood cell counts, e.g., the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), have been reported in RA patients. However, their diagnostic accuracy has not been comprehensively assessed. Therefore, we conducted a systematic review and meta-analysis of studies reporting the sensitivity and specificity of the NLR and PLR, obtained by receiver operating characteristic (ROC) curve analysis, for the presence of RA and active disease. We searched electronic databases from inception to 15 March 2024 and assessed the risk of bias using the JBI Critical Appraisal Checklist (PROSPERO registration number: CRD42024533546). In 15 studies, the NLR exhibited acceptable accuracy for the presence of RA (area under the curve, AUC = 0.76, 95% CI 0.72 to 0.80) and active disease (AUC = 0.70, 95% CI 0.66 to 0.74). The PLR exhibited good accuracy for the presence of RA (AUC = 0.80, 95% CI 0.76 to 0.83). There were insufficient studies to assess the accuracy of the PLR for the presence of active disease. Our systematic review and meta-analysis suggests that the NLR and the PLR are promising biomarkers of RA (NLR and PLR) and active disease (NLR). Further research is required to investigate whether the NLR and PLR can significantly enhance the capacity to diagnose RA and active disease in clinical practice.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10238-024-01478-x.

Keywords

Rheumatoid arthritis
Active disease
Neutrophil
To
Lymphocyte ratio
Platelet
To
Lymphocyte ratio
Diagnostic accuracy
Flinders University Open Access funding enabled and organized by CAUL and its Member Institutions

issue-copyright-statement© Springer Nature Switzerland AG 2024
==== Body
pmcIntroduction

A substantial body of evidence suggests that the early diagnosis of RA and the prompt recognition of increases in disease activity, i.e., active disease, in patients with confirmed RA are essential to prevent or minimize joint damage and disability and improve long-term outcomes [1–5]. However, the limited clinical experience in assessing these patients by non-rheumatologists, particularly in primary care, and the frequent overlap of mild signs and symptoms with other forms of inflammatory polyarthritis represent a significant barrier to accurate diagnosis [1, 5].

In addition to clinical and radiological assessment, several serological tests are available to assist physicians in diagnosing RA and increased disease activity. However, the diagnostic accuracy of such tests could be improved. For example, a systematic review and meta-analysis reported that the pooled sensitivity and specificity of the rheumatoid factor (RF) for the presence of RA were 69% (95% CI, 65% to 73%) and 85% (95% CI, 82% to 88%), respectively. Those of the autoantibodies against cyclic citrullinated peptide (CCP) were 67% (95% CI, 62% to 72%) and 95% (95% CI, 94% to 97%), respectively [6]. The use of conventional biomarkers of inflammation carries similar issues. For example, in a prospective cohort study conducted in primary care in the UK, the area under the curve (AUC) values of the C-reactive protein and the erythrocyte sedimentation rate for the diagnosis of RA were considered less than acceptable, 0.69 (95% CI 0.67 to 0.71) and 0.69 (95% CI 0.67 to 0.71) [7, 8].

In the search for novel, more accurate biomarkers of RA and active disease, several haematological indices derived from blood cell types assessed in routine blood cell counts, particularly neutrophils, platelets, and lymphocytes, are gaining increasing interest as markers of inflammation. Their easy determination and negligible costs have allowed their investigation in different disease states. Two such indices, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), are significantly elevated in several immunological diseases [9–12]. Although similar elevations have been reported in association with RA and RA patients with active disease [13–15], a critical assessment of the diagnostic accuracy of the NLR and PLR in this patient group has not been conducted.

Therefore, we conducted a systematic review and meta-analysis of studies reporting the sensitivity and specificity values of the NLR and PLR from receiver operating characteristic (ROC) curve analysis for the presence of RA and active disease.

Methods

Literature search

We conducted a systematic literature search for articles published in PubMed, Scopus, and Web of Science from inception to the 31st of March 2024, using the following terms: “rheumatoid arthritis” and “neutrophil to lymphocyte ratio” or “neutrophil-to-lymphocyte ratio” or “NLR” or “platelet to lymphocyte ratio” or “platelet-to-lymphocyte ratio” or “PLR”. Two investigators independently screened individual abstracts and full articles according to the following inclusion criteria: (a) studies reporting the diagnostic accuracy of the NLR and PLR by sensitivity and specificity, obtained by receiver operating characteristic (ROC) analysis, for the presence of RA and/or active disease, assessed using conventional tools such as the Disease Activity Score-28 (DAS28) [16], (b) adult participants, and (c) full-text availability of articles written in English language. Additional studies were searched through the references of individual articles.

Data independently extracted from each article included age, male-to-female ratio, publication year, study design (prospective vs. retrospective), study country, number of participants, area under the receiver operating characteristic curve (AUROC) with 95% confidence intervals (CIs), sensitivity, specificity, and cut-off values used for the NLR and PLR. True positive (TP), false positive (FP), false negative (FN), and true negative (TN) values were either extracted or calculated according to the following formulas: Sensitivity = TP/(TP + FN); Specificity = TN/(FP + TN) [17].

Each article’s bias risk was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for case–control studies [18]. We followed the PRISMA 2020 statement [19] (Supplementary Table 1) and registered the protocol in an international repository (PROSPERO registration number: CRD42024533546).

Statistical analysis

The pooled sensitivity and specificity were calculated, and the corresponding forest plot was generated to assess the diagnostic accuracy of the NLR and PLR for the presence of RA and active disease [20]. Summary receiving characteristics (SROC) curves with 95% confidence region and prediction region were generated using the midas command [21]. The relationship between prior probability, likelihood ratio, and posterior test probability was assessed using Fagan’s nomogram plot [22]. Stata 14 was used for statistical analyses (StataCorp LLC, College Station, TX, USA).

Results

Study selection

Our search strategy identified a total of 909 articles, of which 888 were excluded because they presented either duplicate data or irrelevant information. A comprehensive review of the remaining 21 articles led to the further exclusion of six studies due to missing data, leaving 15 studies for further analysis (Fig. 1 and Tables 1, 2) [23–37]. The risk of bias was assessed as low in all studies, barring one which exhibited moderate risk (Supplementary Table 2) [37].Fig. 1 Flow chart of study selection

Table 1 Characteristics of the studies investigating the diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio for the presence of rheumatoid arthritis

Study	Study
design	N	Age (Years)	M/F	AUC (95% CI)
NLR
PLR	Cut-off
NLR
PLR	Sensitivity (%)
NLR
PLR	Specificity (%)
NLR
PLR	
Peng YF et al., 2015, China [24]	P	219	54	71/148	NR

0.847 (0.794–0.901)

	NR

115.66

	NR

0.825

	NR

0.748

	
Chen Q et al., 2019, [25]	P	488	61	101/387	NR

0.676 (NR)

	NR

171.92

	NR

0.6128

	NR

0.8168

	
Erre GL et al., 2020, Italy [26]	P	346	55	123/223	0.67 (0.61–0.73)

0.65 (0.59–0.71)

	1.88

141.4

	0.618

0.462

	0.693

0.857

	
Jin Z et al., 2021, China [29]	R	1254	64	239/1015	0.831 (NR)

NR

	2.13

NR

	0.767

NR

	0.759

NR

	
Lijuan W et al., 2021, China [31]	R	518	54	146/372	NR

0.869 (0.837–0.897)

	NR

NR

	NR

0.9176

	NR

0.7395

	
Song BW et al., 2022, South Korea [32]	R	341	58	NR	0.622 (NR)

0.58 (NR)

	2.07

143.26

	0.623

0.557

	0.614

0.607

	
Xu Y et al., 2022, China [34]	R	1865	60	479/1386	0.847 (0.827–0.866)

NR

	2.28

NR

	0.752

NR

	0.817

NR

	
Obaid J et al., 2023, Yemen [37]	P	82	NR	NR	0.699 (0.571–0.819)

NR

	1.35

NR

	0.574

NR

	0.8

NR

	
Legend: NR, not reported; P, prospective; R, retrospective; M/F, male to female ratio; AUC, area under the curve; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio

Table 2 Characteristics of the studies investigating the diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio for the presence of active disease

Study	Study
design	N	Age
(Years)	M/F	AUC (95% CI)
NLR
PLR	Cut-off
NLR
PLR	Sensitivity (%)
NLR
PLR	Specificity (%)
NLR
PLR	
Chandrashekara S et al., 2015 India [23]	P	88	50	12/76	0.584 (0.474–0.688)

NR

	2.9

NR

	0.3043

NR

	0.8

NR

	
Remalante PPM et al., 2020, Philippines [27]	R	134	56	2/132	0.629 (NR)

NR

	2.32

NR

	0.546

NR

	0.769

NR

	
Dechanuwong P et al., 2021, Thailand [28]	R	325	55	38/287	0.592 (0.527–0.657)

NR

	2.6

NR

	0.752

NR

	0.432

NR

	
Lijuan W et al., 2021, China [30]	R	547	56	102/445	0.6 (NR)

0.597 (NR)

	4.5

167.5

	0.318

0.573

	0.778

0.639

	
Taha SI et al., 2022, Egypt [33]	P	100	67	19/81	0.69 (0.521–0.858)

NR

	3.3

NR

	0.782

NR

	0.538

NR

	
El-Husseiny PN et al., 2023, Egypt, [35]	P	47	44	4/43	0.78 (0.68–0.82)

0.841 (0.6–0.84)

	1.52

121.9

	0.842

0.789

	0.442

0.442

	
Elsayed SA et al., Egypt, 2023 [36]	P	120	43	12/108	0.913 (NR)

0.841 (NR)

	1.3

112.39

	0.869

0.859

	0.81

0.67

	
Legend: NR, not reported; P, prospective; R, retrospective; M/F, male to female ratio; AUC, area under the curve; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio

Neutrophil-to-lymphocyte ratio

Presence of rheumatoid arthritis

Five studies assessing a total of 3888 subjects (2830 RA patients and 1058 healthy controls, 78% females, mean age 60 years) reported the sensitivity and specificity of the NLR for the presence of RA [26, 29, 32, 34, 37] (Table 1). Two studies were performed in China [29, 34], one in Italy [26], one in Korea [32], and one in Yemen [37]. Three studies were retrospective [29, 32, 34], and the remaining two prospective [26, 37].

The pooled sensitivity and specificity for the presence of RA were 0.68 (95% CI 0.61 to 0.75) and 0.72 (95% CI 0.65 to 0.79), respectively (Fig. 2). The SROC curve with 95% confidence region and prediction region showed an AUC value of 0.76 (95% CI 0.72 to 0.80), with the summary operating point at sensitivity of 0.68 and specificity of 0.72 (Fig. 3). Assessment of publication bias and meta-regression analysis could not be performed because of the small number of studies.Fig. 2 Forest plot of the pooled estimates of sensitivity and specificity of the neutrophil-to-lymphocyte ratio for the presence of rheumatoid arthritis

Fig. 3 Summary receiver operating characteristics curve with 95% confidence region and prediction region of the neutrophil-to-lymphocyte ratio for the presence of rheumatoid arthritis

Fagan’s nomogram showed that, assuming a pre-test probability of RA of 25%, the post-test probability was 45% in subjects with relatively high NLR values and 13% in those with relatively low NLR values (Fig. 4).Fig. 4 Fagan’s nomogram of the neutrophil-to-lymphocyte ratio for the presence of rheumatoid arthritis

Active disease

Seven studies assessing a total of 1361 RA patients (933 with active disease, 428 with non-active disease, 86% females, mean age 55 years) reported the sensitivity and specificity of the NLR for active disease [23, 27, 28, 30, 33, 35, 36] (Table 2). Three studies were performed in Egypt [33, 35, 36], one in China [30], one in India [23], one in the Philippines [27], and one in Thailand [28]. Three studies were retrospective [27, 28, 30], whilst four were prospective [23, 33, 35, 36]. In all studies, disease activity was assessed using the DAS28 and a threshold of 2.6 was used to define the presence of active disease.

The pooled sensitivity and specificity of the NLR for active disease were 0.66 (95% CI 0.47 to 0.80) and 0.66 (95% CI 0.52 to 0.77), respectively (Fig. 5). The SROC curve with 95% confidence region and prediction region showed an AUC value of 0.70 (95% CI 0.66 to 0.74) with the summary operating point at sensitivity of 0.66 and specificity of 0.66 (Fig. 6). Assessment of publication bias and meta-regression analysis could not be performed because of the small number of studies.Fig. 5 Forest plot of the pooled estimates of sensitivity and specificity of the neutrophil-to-lymphocyte ratio for the presence of active disease

Fig. 6 Summary receiver operating characteristics curve with 95% confidence region and prediction region of the neutrophil-to-lymphocyte ratio for the presence of active disease

Fagan’s nomogram showed that, assuming a pre-test probability of active disease of 25%, the post-test probability was 39% in subjects with relatively high NLR values and 15% in those with relatively low NLR values (Fig. 7).Fig. 7 Fagan’s nomogram of the neutrophil-to-lymphocyte ratio for the presence of active disease

Platelet-to-lymphocyte ratio

Presence of rheumatoid arthritis

Five studies investigating a total of 1912 subjects (777 RA patients and 1135 healthy controls, 77% females, mean age 57 years) reported the sensitivity and specificity of the PLR for the presence of RA [24–26, 31, 32] (Table 1). Three studies were conducted in China [24, 25, 31], one in Italy [26], and one in Korea [32]. Two studies were retrospective [31, 32], and the remaining three prospective [24–26].

The pooled sensitivity and specificity of the PLR for the presence of RA were 0.71 (95% CI 0.52 to 0.84) and 0.76 (95% CI 0.68 to 0.83), respectively (Fig. 8). The SROC curve with 95% confidence region and prediction region showed an AUC value of 0.80 (95% CI 0.76 to 0.83), with the summary operating point at sensitivity of 0.71 and specificity of 0.76 (Fig. 9). Assessment of publication bias and meta-regression analysis could not be performed because of the small number of studies.Fig. 8 Forest plot of the pooled estimates of sensitivity and specificity of the platelet-to-lymphocyte ratio for the presence of rheumatoid arthritis

Fig. 9 Summary receiver operating characteristics curve with 95% confidence region and prediction region of the platelet-to-lymphocyte ratio for the presence of rheumatoid arthritis

Fagan’s nomogram showed that, assuming a pre-test probability of RA of 25%, the post-test probability was 50% in subjects with relatively high PLR values and 11% in those with relatively low PLR values (Fig. 10).Fig. 10 Fagan’s nomogram of the neutrophil-to-lymphocyte ratio for the presence of rheumatoid arthritis

Active disease

Three studies in a total of 714 RA patients (610 with active disease, 104 with non-active disease, 83% females, mean age 53 years) reported the sensitivity and specificity of the PLR for active disease [30, 35, 36] (Table 2). Two studies were conducted in Egypt and were prospective [35, 36], whereas the third one was conducted in China and was retrospective [30]. In all studies, disease activity was assessed using the DAS28 and a threshold of 2.6 was used to define the presence of active disease.

Forest plots for pooled sensitivity and specificity and the SROC curve could not be generated, given the limited number of studies. Lijuan W et al. reported an AUC value of 0.597 with 0.576 sensitivity and 0.639 specificity [30]. El-Husseiny PN et al. reported an AUC of 0.72 with 0.789 sensitivity and 0.442 specificity [35]. Elsayed SA et al. reported an AUC of 0.841 with 0.859 sensitivity and 0.67 specificity [36].

Discussion

Taken together, the results of our study suggest that haematological indices derived from routine full blood cell counts can be helpful in diagnosing RA and the presence of active disease. Based on the observed AUC [8], the NLR exhibited a moderate diagnostic accuracy for the presence of RA and active disease, whereas the PLR exhibited a good diagnostic accuracy for the presence of RA. There were insufficient studies to assess the accuracy of the PLR for the presence of active disease. These observations support the potential clinical use of the NLR and the PLR, combined with clinical assessment and other serological biomarkers, in diagnosing and managing patients with RA.

A recent systematic review and meta-analysis of 19 studies investigating the diagnostic accuracy of the RF for the presence of RA (4786 RA patients and 6994 controls) reported an AUC for SROC curve of 0.85 (standard error = 0.03). However, pooled analysis of the prognostic accuracy was not performed, given the significant between-study differences in the assessed endpoints (disease activity, radiographic progression, and treatment response) [38]. In another systematic review and meta-analysis of 24 studies investigating the diagnostic accuracy for the presence of RA in 7344 participants, the AUC for SROC curve for anti-CCP or RF was 0.87 (standard error = 0.01) [39]. However, half of the selected studies included patients with other rheumatic diseases as control group, no study used healthy controls as control group, and no assessment of the diagnostic accuracy for active disease was conducted. Further studies are therefore necessary to adequately compare the diagnostic accuracy of the NLR, PLR, RF, and anti-CCP, singly or in combination, in RA patients and control groups with similar characteristics. As previously discussed, the AUC values of the NLR and PLR reported in our systematic review and meta-analysis compare favourably with other non-specific biomarkers of inflammation, i.e., C-reactive protein and erythrocyte sedimentation rate [7, 8].

The potential clinical use of the NLR and PLR is further supported by the information provided by Fagan’s nomogram, which showed a tangible separation in the probability of having RA or active disease given a relatively high NLR and/or PLR. However, these results should prompt the conduct of appropriately designed prospective studies to investigate the added benefits of measuring the NLR and PLR in patients with RA from a clinical and health economics point of view. Such studies should assess the influence of several factors potentially influencing the diagnostic accuracy of these haematological indices. These factors include the use of standard cut-off values and specific clinical and demographic patient characteristics likely to account for the variability in early clinical presentation and disease progression [40–42]. These issues notwithstanding, the cost-effectiveness of measuring the NLR and PLR appears particularly appealing in the evaluation and monitoring of RA patients, given the routine evaluation of full blood cell counts and individual cell types in this group [43].

An additional issue worth investigating is the relative weight and place of measuring the NLR and/or PLR within current algorithms and scoring systems for the diagnosis of RA. For example, the 2010 American College of Rheumatology/European League Against Rheumatology (ACR/EULAR) criteria are primarily based on the number and site of involved joints, elevations of RF and/or anti-CCP, elevations in acute phase reactants (C-reactive protein and erythrocyte sedimentation rate), and symptom duration [44]. Further research is warranted to determine whether the NLR and/or PLR should be measured before, during, or after the assessment of RF, CCP, and acute phase reactants to enhance diagnostic accuracy. Similarly, studies should investigate the ideal place for NLR and/or PLR assessment within current recommendations for disease monitoring and evaluation of treatment response [45].

Neutrophils, platelets, and lymphocytes are involved in the pathophysiology and clinical manifestations of RA. Neutrophils play a critical role in driving inflammatory processes not only in the early stages of RA but also in the progression of the disease. These cells are the most abundant cell type in the synovial fluid of patients with RA, and the elevated expression of chemokines further augments the inflammatory response locally and systemically [46]. Furthermore, neutrophils are responsible for the overproduction of reactive oxygen species, with the consequent alteration of the redox balance, and the formation of neutrophil extracellular traps [47–49]. Similarly, there is a complex interplay between platelet alterations, inflammation, and disease activity in RA as platelets release several inflammatory mediators such as cytokines, chemokines, and growth factors [50–53]. Furthermore, the presence of platelet microparticles in the circulation of RA patients exerts a significant pro-coagulant effect and, at the same time, expresses autoantigens that perpetuate the generation of pro-inflammatory immune complexes involved in synovial inflammation [54, 55]. While a reduction in the lymphocyte count is commonly observed in RA as well as other autoimmune conditions [56], functional alterations of this cell type have been increasingly reported in RA, including dysregulated proliferation and differentiation and excessive inflammatory responses [57, 58]. Further research is required to investigate whether alterations in neutrophil, platelet, and lymphocyte counts, reflected in the modifications of the NLR and PLR, are associated with functional alterations of these cell types and with the clinical manifestations of RA.

One strength of our systematic review and meta-analysis was the comprehensive assessment of the sensitivity and specificity of the NLR and PLR for the presence of RA and active disease, assessed using the AUC and the Fagan’s nomogram, which provides essential information regarding the diagnostic accuracy of these haematological indices. One significant limitation was that all identified studies, except one [26], were conducted in Africa and Asia, which prevents the generalisability of our findings and requires further studies in other geographical locations given the presence of ethnic-related differences in the NLR and PLR in other patient groups [59–62]. A further limitation is the lack of information in our analyses regarding the possible direct influence of common features in RA patients, particularly infections and co-morbidities [63–65], and pharmacological treatments [66, 67], on these haematological indices and, consequently, their diagnostic accuracy.

In conclusion, the results of our systematic review and meta-analysis suggest that the NLR and the PLR have promising diagnostic accuracy for the presence of RA and active disease. However, their routine use in clinical practice requires confirmation and validation in prospective studies investigating the added benefits of these haematological indices within existing algorithms, and the potential influence of concurrent infections, comorbidities, and specific treatments, in diagnosing and managing patients with RA.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 34 KB)

Supplementary file2 (DOCX 17 KB)

Author contributions

AZ and AAM helped in study conception, data interpretation, writing—review & editing; AZ done data collection and analysis; AAM helped in writing—first draft.

Funding

Open Access funding enabled and organized by CAUL and its Member Institutions. No external funding was used.

Data availability

The data that support the findings of this systematic review and meta-analysis are available from AZ upon reasonable request.

Declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval

Ethics approval was not required as this was a systematic review of published studies.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Siddle HJ Bradley SH Anderson AM Mankia K Emery P Richards SH Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice Br J Gen Pract 2023 73 729 152 154 10.3399/bjgp23X732321 36997210
Siddle HJ, Bradley SH, Anderson AM, Mankia K, Emery P, Richards SH. Opportunities and challenges in early diagnosis of rheumatoid arthritis in general practice. Br J Gen Pract. 2023;73(729):152–4. 10.3399/bjgp23X732321.36997210 10.3399/bjgp23X732321
2. Monti S Montecucco C Bugatti S Caporali R Rheumatoid arthritis treatment: the earlier the better to prevent joint damage RMD Open 2015 1 Suppl 1 e000057 10.1136/rmdopen-2015-000057 26557378
Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057. 10.1136/rmdopen-2015-000057.26557378 10.1136/rmdopen-2015-000057
3. Aletaha D Smolen JS Diagnosis and Management of Rheumatoid Arthritis: A Review JAMA 2018 320 13 1360 1372 10.1001/jama.2018.13103 30285183
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360–72. 10.1001/jama.2018.13103.30285183 10.1001/jama.2018.13103
4. Aletaha D Ward MM Machold KP Nell VP Stamm T Smolen JS Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states Arthritis Rheum 2005 52 9 2625 2636 10.1002/art.21235 16142705
Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36. 10.1002/art.21235.16142705 10.1002/art.21235
5. Mian A Ibrahim F Scott DL A systematic review of guidelines for managing rheumatoid arthritis BMC Rheumatol 2019 3 42 10.1186/s41927-019-0090-7 31660534
Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42. 10.1186/s41927-019-0090-7.31660534 10.1186/s41927-019-0090-7
6. Nishimura K Sugiyama D Kogata Y Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis Ann Intern Med 2007 146 11 797 808 10.7326/0003-4819-146-11-200706050-00008 17548411
Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808. 10.7326/0003-4819-146-11-200706050-00008.17548411 10.7326/0003-4819-146-11-200706050-00008
7. Watson J Jones HE Banks J Whiting P Salisbury C Hamilton W Use of multiple inflammatory marker tests in primary care: using clinical practice research datalink to evaluate accuracy Br J Gen Pract 2019 69 684 e462 e469 10.3399/bjgp19X704309 31208975
Watson J, Jones HE, Banks J, Whiting P, Salisbury C, Hamilton W. Use of multiple inflammatory marker tests in primary care: using clinical practice research datalink to evaluate accuracy. Br J Gen Pract. 2019;69(684):e462–9. 10.3399/bjgp19X704309.31208975 10.3399/bjgp19X704309
8. Mandrekar JN Receiver operating characteristic curve in diagnostic test assessment J Thorac Oncol 2010 5 9 1315 1316 10.1097/JTO.0b013e3181ec173d 20736804
Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–6. 10.1097/JTO.0b013e3181ec173d.20736804 10.1097/JTO.0b013e3181ec173d
9. Bilge M Yesilova A Adas M Helvaci A Neutrophil- and platelet- to lymphocyte ratio in patients with euthyroid hashimoto’s thyroiditis Exp Clin Endocrinol Diabetes 2019 127 8 545 549 10.1055/a-0723-3441 30267388
Bilge M, Yesilova A, Adas M, Helvaci A. Neutrophil- and platelet- to lymphocyte ratio in patients with euthyroid hashimoto’s thyroiditis. Exp Clin Endocrinol Diabetes. 2019;127(8):545–9. 10.1055/a-0723-3441.30267388 10.1055/a-0723-3441
10. Onalan E Donder E Neutrophil and platelet to lymphocyte ratio in patients with hypothyroid Hashimoto’s thyroiditis Acta Biomed 2020 91 2 310 314 10.23750/abm.v91i2.8592 32420966
Onalan E, Donder E. Neutrophil and platelet to lymphocyte ratio in patients with hypothyroid Hashimoto’s thyroiditis. Acta Biomed. 2020;91(2):310–4. 10.23750/abm.v91i2.8592.32420966 10.23750/abm.v91i2.8592
11. Hasselbalch IC Sondergaard HB Koch-Henriksen N The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis Mult Scler J Exp Transl Clin 2018 4 4 2055217318813183 10.1177/2055217318813183 30515298
Hasselbalch IC, Sondergaard HB, Koch-Henriksen N, et al. The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(4):2055217318813183. 10.1177/2055217318813183.30515298 10.1177/2055217318813183
12. Zeng Z Wang C Wang B Prediction of neutrophil-to-lymphocyte ratio in the diagnosis and progression of autoimmune encephalitis Neurosci Lett 2019 694 129 135 10.1016/j.neulet.2018.12.003 30521947
Zeng Z, Wang C, Wang B, et al. Prediction of neutrophil-to-lymphocyte ratio in the diagnosis and progression of autoimmune encephalitis. Neurosci Lett. 2019;694:129–35. 10.1016/j.neulet.2018.12.003.30521947 10.1016/j.neulet.2018.12.003
13. Erre GL Paliogiannis P Castagna F Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis Eur J Clin Invest 2019 49 1 e13037 10.1111/eci.13037 30316204
Erre GL, Paliogiannis P, Castagna F, et al. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest. 2019;49(1):e13037. 10.1111/eci.13037.30316204 10.1111/eci.13037
14. Zinellu A Mangoni AA Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio and disease activity in rheumatoid arthritis: A systematic review and meta-analysis Eur J Clin Invest 2023 53 2 e13877 10.1111/eci.13877 36121342
Zinellu A, Mangoni AA. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio and disease activity in rheumatoid arthritis: A systematic review and meta-analysis. Eur J Clin Invest. 2023;53(2):e13877. 10.1111/eci.13877.36121342 10.1111/eci.13877
15. Liu X Li J Sun L Wang T Liang W The association between neutrophil-to-lymphocyte ratio and disease activity in rheumatoid arthritis Inflammopharmacology 2023 31 5 2237 2244 10.1007/s10787-023-01273-2 37418101
Liu X, Li J, Sun L, Wang T, Liang W. The association between neutrophil-to-lymphocyte ratio and disease activity in rheumatoid arthritis. Inflammopharmacology. 2023;31(5):2237–44. 10.1007/s10787-023-01273-2.37418101 10.1007/s10787-023-01273-2
16. Dougados M Aletaha D van Riel P Disease activity measures for rheumatoid arthritis Clin Exp Rheumatol 2007 25 5 S22 9 17977485
Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(5):S22-9.17977485
17. Trevethan R Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice Front Public Health 2017 5 307 10.3389/fpubh.2017.00307 29209603
Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. 10.3389/fpubh.2017.00307.29209603 10.3389/fpubh.2017.00307
18. Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer’s Manual. Adelaide, Australia: Johanna Briggs Institute; 2017.
19. Page MJ McKenzie JE Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021 372 n71 10.1136/bmj.n71 33782057
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71.33782057 10.1136/bmj.n71
20. Leeflang MM Systematic reviews and meta-analyses of diagnostic test accuracy Clin Microbiol Infect 2014 20 2 105 113 10.1111/1469-0691.12474 24274632
Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 2014;20(2):105–13. 10.1111/1469-0691.12474.24274632 10.1111/1469-0691.12474
21. Dwamena AB, Sylvester R, Carlos RC. midas: meta-analysis of diagnostic accuracy studies2009 8 April 2024:[2–25 pp.]
22. Fagan TJ Letter: nomogram for bayes’s theorem N Engl J Med 1975 293 5 257 10.1056/NEJM197507312930513 1143310
Fagan TJ. Letter: nomogram for bayes’s theorem. N Engl J Med. 1975;293(5):257. 10.1056/NEJM197507312930513.1143310 10.1056/NEJM197507312930513
23. Chandrashekara S Rajendran A Bai Jaganath A Krishnamurthy R Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis Reumatismo 2015 67 3 109 115 10.4081/reumatismo.2015.838 26876190
Chandrashekara S, Rajendran A, Bai Jaganath A, Krishnamurthy R. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis. Reumatismo. 2015;67(3):109–15. 10.4081/reumatismo.2015.838.26876190 10.4081/reumatismo.2015.838
24. Peng YF Cao L Zeng YH Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with rheumatoid arthritis Open Med (Wars) 2015 10 1 249 253 10.1515/med-2015-0037 28352702
Peng YF, Cao L, Zeng YH, et al. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with rheumatoid arthritis. Open Med (Wars). 2015;10(1):249–53. 10.1515/med-2015-0037.28352702 10.1515/med-2015-0037
25. Chen Q Chen DY Xu XZ Liu YY Yin TT Li D Platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/lymphocyte ratios as biomarkers in patients with rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease Med Sci Monit 2019 25 6474 6481 10.12659/MSM.916583 31462627
Chen Q, Chen DY, Xu XZ, Liu YY, Yin TT, Li D. Platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/lymphocyte ratios as biomarkers in patients with rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease. Med Sci Monit. 2019;25:6474–81. 10.12659/MSM.916583.31462627 10.12659/MSM.916583
26. Erre GL Buscetta G Mangoni AA Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: a cross-sectional study Medicine (Baltimore) 2020 99 44 e22557 10.1097/MD.0000000000022557 33126304
Erre GL, Buscetta G, Mangoni AA, et al. Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: a cross-sectional study. Medicine (Baltimore). 2020;99(44):e22557. 10.1097/MD.0000000000022557.33126304 10.1097/MD.0000000000022557
27. Remalante PPM Salido EO Penserga EG Gauiran DTV Red cell distribution width and neutrophil-lymphocyte ratio in rheumatoid arthritis Rheumatol Int 2020 40 10 1631 1637 10.1007/s00296-020-04685-3 32812079
Remalante PPM, Salido EO, Penserga EG, Gauiran DTV. Red cell distribution width and neutrophil-lymphocyte ratio in rheumatoid arthritis. Rheumatol Int. 2020;40(10):1631–7. 10.1007/s00296-020-04685-3.32812079 10.1007/s00296-020-04685-3
28. Dechanuwong P Phuan-Udom R Hematological parameters as a predictor of disease remission in patients with rheumatoid arthritis Ann Med Surg (Lond) 2021 72 103085 10.1016/j.amsu.2021.103085 34868575
Dechanuwong P, Phuan-Udom R. Hematological parameters as a predictor of disease remission in patients with rheumatoid arthritis. Ann Med Surg (Lond). 2021;72:103085. 10.1016/j.amsu.2021.103085.34868575 10.1016/j.amsu.2021.103085
29. Jin Z Cai G Zhang P The value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as complementary diagnostic tools in the diagnosis of rheumatoid arthritis: a multicenter retrospective study J Clin Lab Anal 2021 35 1 e23569 10.1002/jcla.23569 32951253
Jin Z, Cai G, Zhang P, et al. The value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as complementary diagnostic tools in the diagnosis of rheumatoid arthritis: a multicenter retrospective study. J Clin Lab Anal. 2021;35(1):e23569. 10.1002/jcla.23569.32951253 10.1002/jcla.23569
30. Lijuan W Yuting Z Chaoyang L Ju Y Neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios may not be useful markers to assess disease activity in rheumatoid arthritis: A STROBE-compliant article Medicine (Baltimore) 2021 100 45 e27631 10.1097/MD.0000000000027631 34766563
Lijuan W, Yuting Z, Chaoyang L, Ju Y. Neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios may not be useful markers to assess disease activity in rheumatoid arthritis: A STROBE-compliant article. Medicine (Baltimore). 2021;100(45):e27631. 10.1097/MD.0000000000027631.34766563 10.1097/MD.0000000000027631
31. Zhou W Li X Jiang Y The significance of blood index and biochemistry index in patients with rheumatoid arthritis Clin Lab 2021 67 12 2644 50
Zhou W, Li X, Jiang Y, et al. The significance of blood index and biochemistry index in patients with rheumatoid arthritis. Clin Lab. 2021;67(12):2644–50.
32. Song BW Kim AR Kim YK Diagnostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte, and monocyte-to-lymphocyte ratios for the assessment of rheumatoid arthritis in patients with undifferentiated inflammatory arthritis Diagnostics (Basel) 2022 10.3390/diagnostics12071702 36553140
Song BW, Kim AR, Kim YK, et al. Diagnostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte, and monocyte-to-lymphocyte ratios for the assessment of rheumatoid arthritis in patients with undifferentiated inflammatory arthritis. Diagnostics (Basel). 2022. 10.3390/diagnostics12071702.36553140 10.3390/diagnostics12071702
33. Taha SI Samaan SF Ibrahim RA Moustafa NM El-Sehsah EM Youssef MK Can complete blood count picture tell us more about the activity of rheumatological diseases? Clin Med Insights Arthritis Musculoskelet Disord 2022 15 11795441221089182 10.1177/11795441221089182 35481333
Taha SI, Samaan SF, Ibrahim RA, Moustafa NM, El-Sehsah EM, Youssef MK. Can complete blood count picture tell us more about the activity of rheumatological diseases? Clin Med Insights Arthritis Musculoskelet Disord. 2022;15:11795441221089182. 10.1177/11795441221089182.35481333 10.1177/11795441221089182
34. Xu Y He H Zang Y Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study Clin Rheumatol 2022 41 7 1989 2000 10.1007/s10067-022-06122-1 35266094
Xu Y, He H, Zang Y, et al. Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study. Clin Rheumatol. 2022;41(7):1989–2000. 10.1007/s10067-022-06122-1.35266094 10.1007/s10067-022-06122-1
35. El-Husseiny PN Al-Adle SS Eesa NN Gheita TA Clinical significance of the lipid profile, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in different rheumatic disease patients Romanian J Rheumatol 2023 32 4 161 172 10.37897/rjr.2023.4.8
El-Husseiny PN, Al-Adle SS, Eesa NN, Gheita TA. Clinical significance of the lipid profile, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in different rheumatic disease patients. Romanian J Rheumatol. 2023;32(4):161–72. 10.37897/rjr.2023.4.8.10.37897/rjr.2023.4.8
36. Elsayed SA Basily SM Esmail MA Mounir O Platelet/lymphocyte, neutrophil/lymphocyte, and lymphocyte/monocyte ratios as biomarkers for rheumatoid arthritis: correlation with disease activity Egypt Rheumatol Rehabilitat 2023 10.1186/s43166-023-00207-8
Elsayed SA, Basily SM, Esmail MA, Mounir O. Platelet/lymphocyte, neutrophil/lymphocyte, and lymphocyte/monocyte ratios as biomarkers for rheumatoid arthritis: correlation with disease activity. Egypt Rheumatol Rehabilitat. 2023. 10.1186/s43166-023-00207-8.10.1186/s43166-023-00207-8
37. Obaid J Almjydy MMA Garban MAQ Al-Hebari FSQ Al-Washah NAH Neutrophil-to-monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity Health Sci Rep 2023 6 8 e1478 10.1002/hsr2.1478 37547362
Obaid J, Almjydy MMA, Garban MAQ, Al-Hebari FSQ, Al-Washah NAH. Neutrophil-to-monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity. Health Sci Rep. 2023;6(8): e1478. 10.1002/hsr2.1478.37547362 10.1002/hsr2.1478
38. Motta F Bizzaro N Giavarina D Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis RMD Open 2023 10.1136/rmdopen-2022-002817 37541740
Motta F, Bizzaro N, Giavarina D, et al. Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open. 2023. 10.1136/rmdopen-2022-002817.37541740 10.1136/rmdopen-2022-002817
39. Sun J Zhang Y Liu L Liu G Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis Clin Exp Rheumatol 2014 32 1 11 21 24050751
Sun J, Zhang Y, Liu L, Liu G. Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2014;32(1):11–21.24050751
40. Taylor PC Update on the diagnosis and management of early rheumatoid arthritis Clin Med (Lond) 2020 20 6 561 564 10.7861/clinmed.2020-0727 33199320
Taylor PC. Update on the diagnosis and management of early rheumatoid arthritis. Clin Med (Lond). 2020;20(6):561–4. 10.7861/clinmed.2020-0727.33199320 10.7861/clinmed.2020-0727
41. Weman L Salo H Kuusalo L Initial presentation of early rheumatoid arthritis PLoS ONE 2023 18 7 e0287707 10.1371/journal.pone.0287707 37410796
Weman L, Salo H, Kuusalo L, et al. Initial presentation of early rheumatoid arthritis. PLoS ONE. 2023;18(7):e0287707. 10.1371/journal.pone.0287707.37410796 10.1371/journal.pone.0287707
42. Edwards CJ Kiely P Arthanari S Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review Rheumatol Adv Pract 2019 3 1 rkz002 10.1093/rap/rkz002 31431990
Edwards CJ, Kiely P, Arthanari S, et al. Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. Rheumatol Adv Pract. 2019;3(1):rkz002. 10.1093/rap/rkz002.31431990 10.1093/rap/rkz002
43. Shahrabi S Saki N Safa M Pezeshki SMS Complete blood count test in rheumatology: not just a screening test Clin Lab 2023 10.7754/Clin.Lab.2022.221012 37307116
Shahrabi S, Saki N, Safa M, Pezeshki SMS. Complete blood count test in rheumatology: not just a screening test. Clin Lab. 2023. 10.7754/Clin.Lab.2022.221012.37307116 10.7754/Clin.Lab.2022.221012
44. Aletaha D Neogi T Silman AJ 2010 rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative Ann Rheum Dis 2010 69 9 1580 1588 10.1136/ard.2010.138461 20699241
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. 10.1136/ard.2010.138461.20699241 10.1136/ard.2010.138461
45. Fraenkel L Bathon JM England BR american college of rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 2021 73 7 924 939 10.1002/acr.24596 34101387
Fraenkel L, Bathon JM, England BR, et al. american college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–39. 10.1002/acr.24596.34101387 10.1002/acr.24596
46. Birkelund S Bennike TB Kastaniegaard K Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients Clin Proteomics 2020 17 29 10.1186/s12014-020-09292-9 32782445
Birkelund S, Bennike TB, Kastaniegaard K, et al. Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients. Clin Proteomics. 2020;17:29. 10.1186/s12014-020-09292-9.32782445 10.1186/s12014-020-09292-9
47. Wright HL Lyon M Chapman EA Moots RJ Edwards SW Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines, reactive oxygen species, and neutrophil extracellular traps Front Immunol 2020 11 584116 10.3389/fimmu.2020.584116 33469455
Wright HL, Lyon M, Chapman EA, Moots RJ, Edwards SW. Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines, reactive oxygen species, and neutrophil extracellular traps. Front Immunol. 2020;11:584116. 10.3389/fimmu.2020.584116.33469455 10.3389/fimmu.2020.584116
48. Kumar S Dikshit M Metabolic insight of neutrophils in health and disease Front Immunol 2019 10 2099 10.3389/fimmu.2019.02099 31616403
Kumar S, Dikshit M. Metabolic insight of neutrophils in health and disease. Front Immunol. 2019;10:2099. 10.3389/fimmu.2019.02099.31616403 10.3389/fimmu.2019.02099
49. O’Neil LJ Kaplan MJ Neutrophils in rheumatoid arthritis: breaking immune tolerance and fueling disease Trends Mol Med 2019 25 3 215 227 10.1016/j.molmed.2018.12.008 30709614
O’Neil LJ, Kaplan MJ. Neutrophils in rheumatoid arthritis: breaking immune tolerance and fueling disease. Trends Mol Med. 2019;25(3):215–27. 10.1016/j.molmed.2018.12.008.30709614 10.1016/j.molmed.2018.12.008
50. Lindemann S Tolley ND Dixon DA Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis J Cell Biol 2001 154 3 485 490 10.1083/jcb.200105058 11489912
Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154(3):485–90. 10.1083/jcb.200105058.11489912 10.1083/jcb.200105058
51. Rosengren S Corr M Boyle DL Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes Arthritis Res Ther 2010 12 2 R65 10.1186/ar2981 20380722
Rosengren S, Corr M, Boyle DL. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther. 2010;12(2):R65. 10.1186/ar2981.20380722 10.1186/ar2981
52. Brown AJ Sepuru KM Sawant KV Rajarathnam K Platelet-derived chemokine CXCL7 dimer preferentially exists in the glycosaminoglycan-bound form: implications for neutrophil-platelet crosstalk Front Immunol 2017 8 1248 10.3389/fimmu.2017.01248 29038657
Brown AJ, Sepuru KM, Sawant KV, Rajarathnam K. Platelet-derived chemokine CXCL7 dimer preferentially exists in the glycosaminoglycan-bound form: implications for neutrophil-platelet crosstalk. Front Immunol. 2017;8:1248. 10.3389/fimmu.2017.01248.29038657 10.3389/fimmu.2017.01248
53. Olumuyiwa-Akeredolu OO Page MJ Soma P Pretorius E Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis Nat Rev Rheumatol 2019 15 4 237 248 10.1038/s41584-019-0187-9 30824879
Olumuyiwa-Akeredolu OO, Page MJ, Soma P, Pretorius E. Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(4):237–48. 10.1038/s41584-019-0187-9.30824879 10.1038/s41584-019-0187-9
54. Boilard E Larabee K Shnayder R Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation J Immunol 2011 186 7 4361 4366 10.4049/jimmunol.1002857 21357261
Boilard E, Larabee K, Shnayder R, et al. Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol. 2011;186(7):4361–6. 10.4049/jimmunol.1002857.21357261 10.4049/jimmunol.1002857
55. Walker B Towhid ST Schmid E Dynamic adhesion of eryptotic erythrocytes to immobilized platelets via platelet phosphatidylserine receptors Am J Physiol Cell Physiol 2014 306 3 C291 C297 10.1152/ajpcell.00318.2013 24284794
Walker B, Towhid ST, Schmid E, et al. Dynamic adhesion of eryptotic erythrocytes to immobilized platelets via platelet phosphatidylserine receptors. Am J Physiol Cell Physiol. 2014;306(3):C291–7. 10.1152/ajpcell.00318.2013.24284794 10.1152/ajpcell.00318.2013
56. Schulze-Koops H Lymphopenia and autoimmune diseases Arthritis Res Ther 2004 6 4 178 180 10.1186/ar1208 15225363
Schulze-Koops H. Lymphopenia and autoimmune diseases. Arthritis Res Ther. 2004;6(4):178–80. 10.1186/ar1208.15225363 10.1186/ar1208
57. Ponchel F Morgan AW Bingham SJ Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis Blood 2002 100 13 4550 4556 10.1182/blood-2002-03-0671 12393721
Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood. 2002;100(13):4550–6. 10.1182/blood-2002-03-0671.12393721 10.1182/blood-2002-03-0671
58. Szabo-Taylor KE Eggleton P Turner CA Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes Int J Biochem Cell Biol 2012 44 8 1223 1231 10.1016/j.biocel.2012.04.016 22565169
Szabo-Taylor KE, Eggleton P, Turner CA, et al. Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes. Int J Biochem Cell Biol. 2012;44(8):1223–31. 10.1016/j.biocel.2012.04.016.22565169 10.1016/j.biocel.2012.04.016
59. Azab B Camacho-Rivera M Taioli E average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of united states subjects PLoS ONE 2014 9 11 e112361 10.1371/journal.pone.0112361 25375150
Azab B, Camacho-Rivera M, Taioli E. average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of united states subjects. PLoS ONE. 2014;9(11):e112361. 10.1371/journal.pone.0112361.25375150 10.1371/journal.pone.0112361
60. Misumida N Kobayashi A Kanei Y Racial differences in the neutrophil-to-lymphocyte ratio in patients with non-ST-segment elevation myocardial infarction Coron Artery Dis 2015 26 5 381 385 10.1097/MCA.0000000000000237 25734607
Misumida N, Kobayashi A, Kanei Y. Racial differences in the neutrophil-to-lymphocyte ratio in patients with non-ST-segment elevation myocardial infarction. Coron Artery Dis. 2015;26(5):381–5. 10.1097/MCA.0000000000000237.25734607 10.1097/MCA.0000000000000237
61. Brinn A Stone J Neutrophil-lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records BMJ Open 2020 10 7 e036859 10.1136/bmjopen-2020-036859 32690528
Brinn A, Stone J. Neutrophil-lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records. BMJ Open. 2020;10(7):e036859. 10.1136/bmjopen-2020-036859.32690528 10.1136/bmjopen-2020-036859
62. Gu X Sun S Gao XS Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients Sci Rep 2016 6 23893 10.1038/srep23893 27025911
Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6:23893. 10.1038/srep23893.27025911 10.1038/srep23893
63. Russell CD Parajuli A Gale HJ The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis J Infect 2019 78 5 339 348 10.1016/j.jinf.2019.02.006 30802469
Russell CD, Parajuli A, Gale HJ, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis. J Infect. 2019;78(5):339–48. 10.1016/j.jinf.2019.02.006.30802469 10.1016/j.jinf.2019.02.006
64. Zinellu A Mangoni AA A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progression and mortality Expert Rev Clin Immunol 2022 18 11 1187 1202 10.1080/1744666X.2022.2120472 36047369
Zinellu A, Mangoni AA. A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progression and mortality. Expert Rev Clin Immunol. 2022;18(11):1187–202. 10.1080/1744666X.2022.2120472.36047369 10.1080/1744666X.2022.2120472
65. Buonacera A Stancanelli B Colaci M Malatino L Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases Int J Mol Sci 2022 10.3390/ijms23073636 35408994
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022. 10.3390/ijms23073636.35408994 10.3390/ijms23073636
66. Lo YT Lim VY Ng M A prognostic model using post-steroid neutrophil-lymphocyte ratio predicts overall survival in primary central nervous system lymphoma Cancers (Basel) 2022 10.3390/cancers14071818 36612137
Lo YT, Lim VY, Ng M, et al. A prognostic model using post-steroid neutrophil-lymphocyte ratio predicts overall survival in primary central nervous system lymphoma. Cancers (Basel). 2022. 10.3390/cancers14071818.36612137 10.3390/cancers14071818
67. Hoffmann JHO Knoop C Enk A Hadaschik EN Detailed long-term dynamics of neutrophil-to-lymphocyte ratio under biologic treatment reveals differential effects of tumour necrosis factor-alpha and interleukin 12/23 antagonists Acta Derm Venereol 2021 101 10 adv00568 10.2340/actadv.v101.271 34590148
Hoffmann JHO, Knoop C, Enk A, Hadaschik EN. Detailed long-term dynamics of neutrophil-to-lymphocyte ratio under biologic treatment reveals differential effects of tumour necrosis factor-alpha and interleukin 12/23 antagonists. Acta Derm Venereol. 2021;101(10):adv00568. 10.2340/actadv.v101.271.34590148 10.2340/actadv.v101.271
